Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Cowen's 2013 Asia Pacific Life Science Showcase
13 slides from Genetic Technologies's conference presentation, Jan 7, 2013
Slide 1: ASX Announcement: Presentation at Cowen's 2013 Asia Pacific Life Science Showcase
For personal use only ASX ANNOUNCEMENT January 7th, 2013 ___________________________________________________________________________________ Presentation at Cowen’s 2013 Asia Pacific Life Science Showcase Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) advises that its Chief Executive Officer,
Slide 2: Breast Cancer Risk. An Emerging Market Segment. Corporate Overview
For personal use only Genetic Technologies presents: Breast Cancer Risk. Corporate An Emerging Overview Market Segment. January 7th, 2013
Slide 3: Forward Looking Statements
Forward Looking Statements For personal use only This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business ach
Slide 4: Corporate Overview
Corporate Overview For personal use only Global diagnostics testing business focused on women’s health NASDAQ: GENE ; ASX: GTG Headquartered in Melbourne, Australia Sales operations in U.S. (via subsidiary, Phenogen Sciences) & Australia TM Lead product, BREVAGen , a non-familial breast ca
Slide 5: What is BREVAGen?
What is BREVAGen? For personal use only Produces both a 5 year and lifetime percentage risk of developing breast cancer Allows physicians to recommend a personalized ‘Breast Health Plan’ outlining better surveillance strategies and proactive changes, tailored to each patient’s lifestyle Uses i
Slide 6: BREVAGen Clinical Validation Study: JNCI
BREVAGen Clinical Validation Study: JNCI October, 2010 For personal use only First fully prospectively-validated SNP panel to be published in a major journal Conducted a 3,300 patient clinical validation trial in U.S., including 1,664 postmenopausal women, as well as a control group of 1,636 can
Slide 7: BREVAGen Makes a Clinical Difference
BREVAGen Makes a Clinical Difference For personal use only A Breast Health Plan motivates women to adopt physician recommendations Detecting breast cancer early is the key to fighting it Only 59% of women have had a mammogram BREVAGen helps solve the over/under use of the mammography debate
Slide 8: Genetic Testing Business
Genetic Testing Business For personal use only Dominant market positions established across PacRim region Globally accredited laboratory Decades of experience producing & selling genetic tests Oncology testing Australia, Asia & EU Contracted provider to NSW Police Force for volume crime fo
Slide 9: IP Licensing
IP Licensing For personal use only Non-coding DNA patent estate provides substantial non-dilutive funding Over 70 licenses, $70M+ revenue received to date Contracted annuity stream of $5.0M through 2015 Further U.S. and EU activities ramping up in 2013 Number Title Expiration date ‘762 Genet
Slide 10: Partner-Ready Research Assets
Partner-Ready Research Assets For personal use only RareCellect™: Next-gen prenatal testing Current market offers testing at 11-13 weeks into pregnancy with a 20% missed abnormality rate. Invasive tests cause up to 8% miscarriage rate (average 1.5%) RareCellect offers an earlier risk free meth
Slide 11: Financial Snapshot
Financial Snapshot For personal use only Financials (five months to November 30) Share Register (AUD millions) 2012 2011 Shares outstanding 475.0 million Revenue / gains 5.1 3.3 ADRs (@30:1 ratio) 15.8 million Operations 1.6 1.6 Top 20 shareholders 69.7% Licensing 3.5 1.7 Total shareholders 3,020 Ne
Slide 12: Growth Strategy
Growth Strategy For personal use only BREVAGen™ market development Build on successful launch Expand territories and specific women’s health channels Expand and develop BREVAGen #2 – increased SNPs; additional ethnicities Assessing new product acquisitions On or close to market assets
Slide 13: Contact Information
For personal use only Contact Information Alison Mew Chief Executive Officer Email: info@gtglabs.com Phone +61 3 8412 7025 Web: www.gtgcorporate.com
Genetic Technologies — Cowen's 2013 Asia Pacific Life Science Showcase on 6ix